The BTK inhibitor originated in America and rose in Europe and Asia-Pacific. The United States currently accounts for 53% of the global BTK inhibitor market. After BTK inhibitor was discovered for the first time In 1993, Beijing Sailintai Medicine, Onepharm/Gliead, Principia Biopharma Bristol-Myers Squibb, Merck , Lilly/Hanmi ,Roche, Takeda, Biological Principia biopharma Eisen, Zhejiang Ming Guide Medicine Science and Technology, Jiangsu Hengrui developed one after another.
The BTK inhibitor is used in Non-hodgkin’s lymphoma (NHL), Wm. Abc-Dlbcl, MMMCL, Fahrenheit macroglobulinemia, b-cell lymphoma, b-cell lymphoma, Sjogren’s Syndrome, Scarring Ulcer Vulva Rheumatoid Arthritis MCL, CLL rheumatoid arthritis autoimmune diseases.
According to 2019 data released by the CAP, the global market for BTK inhibitors is $5.4 billion. Most markets are concentrated in developed countries such as North America and Europe.
In recent years, with the continuous development of biotechnology and drug development in emerging markets, other countries except Europe and the United States are also growing rapidly. The United States became the main market for BTK inhibitor, while the population of the BRIC countries with large populations is also increasing the demand for BTK inhibitor.
Ibrutinib was launched in China in 2017 for the treatment of relapsed refractory CLL/SLL, refractory MCL and WM, and was listed in the national directory of medicare at the end of 2018. It is the only BTK inhibitor sold in China as of September 30, 2019. China is the fastest growing market in this area. Baiji shenzhou has carried out Zanubrutinib and Ibrutinib on the two indications of WM and CLL. In addition to baiji shenzhou, btk-targeted drugs of many domestic pharmaceutical companies, including nuocheng jianhua, hengrui pharmaceutical, zhejiang dawing and Xinovi, have entered the clinical stage and are expected to be launched after 2020.
The following players are covered in this report:
- Johnson & Johnson
- Bristol- Myers Squibb
- Gilead Sciences
- ACEA Biosciences
- Acerta Pharma
- Aptose Biosciences
- Carna Biosciences
- Celgene Corporation
- Eternity Bioscience
- Hanmi Pharmaceutical
- KBP Biosciences
- Loxo Oncology
- LSK BioPharma
- Ono Pharmaceutical
- Principia Biopharma
- Zhejiang DTRM Biopharma
Bruton’s Tyrosine Kinase (Btk) Inhibitors Breakdown Data by Type
- 1nM< IC50<5nM
Bruton’s Tyrosine Kinase (Btk) Inhibitors Breakdown Data by Application
- Chronic Lymphocytic Leukemia (cll)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
- Other Selective B Cell Malignancies
- Chronic Graft-versus-host Disease
Rahul Singh – Digital Marketing Director
Contact: +91 7028 920 828
Sales Contact US:
USA Registered Office: QY Research, INC.
17890 Castleton, Suite 218,
City of industry, CA – 91748
Emails – email@example.com
Web – www.qyresearch.com